TLSI Overview

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. It is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.

Wall Street analysts forecast TLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSI is11.92 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

TriSalus Life Sciences Inc revenue for the last quarter amounts to 8.90M USD, decreased -2.92

TriSalus Life Sciences Inc. EPS for the last quarter amounts to 0.03 USD, decreased -107.69

TriSalus Life Sciences Inc (TLSI) has 102 emplpoyees as of May 13 2026.

Today TLSI has the market capitalization of 280.05M USD.